Eli Lilly reported higher revenue and net income in its latest quarter, with strong demand for its GLP-1 medicines continuing to drive results. The company’s performance was supported by ongoing interest in Mounjaro and Zepbound, two products that have become central to Lilly’s growth story.
Demand for GLP-1 weight-loss and related treatments has remained elevated, and Lilly appears to be benefiting directly from that trend. The latest quarterly update suggests the company is still seeing robust sales momentum for its newer therapies.
Mounjaro and Zepbound have been closely watched by investors and the broader pharmaceutical industry because of their role in the fast-growing market for obesity and metabolic treatments. Continued uptake of these drugs has helped strengthen Lilly’s recent financial performance.
The results reinforce how important GLP-1 products have become for major drugmakers. For Eli Lilly, the latest quarter points to sustained consumer and market demand as Mounjaro and Zepbound continue to support revenue growth.
